Identification of TPI1 As a potential therapeutic target in pancreatic cancer with dependency of TP53 mutation using multi‐omics analysis
Cancer Science · 2024
DOI: 10.1111/cas.16302 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Tomoaki Toyoda und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioregulation, Graduate School of Medicine, Nippon Medical School, Bunkyo-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Tumor Suppressor Protein p53, Carcinoma, Pancreatic Ductal, Mutation. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Mutations of KRAS , CDKN2A , TP53 , and SMAD4 are the four major driver genes for pancreatic ductal adenocarcinoma (PDAC), of which mutations of KRAS and TP53 are the most frequently recognized. However, molecular‐targeted therapies for mutations of KRAS and TP53 have not yet been developed. To identify novel molecular targets, we newly established organoids with the Kras mutation ( Kras mu OR) and Trp53 loss of function using Cre transduction and CRISPR/Cas9 ( Kras mu / p53 mu OR) from murine epithelia of the pancreatic duct in Kras LSL‐G12D mice, and then analyzed the proteomic and metabolomic profiles in both organoids by mass spectrometry. Hyperfunction of the glycolysis pathway was recognized in Kras mu / p53 mu OR compared with Kras mu OR. Loss of function of triosephosphate isomerase (TPI1), which is involved in glycolysis, induced a reduction of cell proliferation in human PDAC cell lines with the TP53 mutation, but not in PDAC or in human fibroblasts without TP53 mutation. The TP53 mutation is clinically recognized in 70% of patients with PDAC. In the present study, protein expression of TPI1 and nuclear accumulation of p53 were recognized in the same patients with PDAC. TPI1 is a potential candidate therapeutic target for PDAC with the TP53 mutation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioregulation, Graduate School of Medicine, Nippon Medical School, Bunkyo-ku, Tokyo, Japan.
- Department of Oral Pathobiological Science and Surgery, Tokyo Dental College, Tokyo, Japan.
- Department of Bioregulation, Institute for Advanced Medical Sciences, Nippon Medical School, Bunkyo-ku, Tokyo, Japan.
- Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Kanazawa-ku, Japan.
- Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
- Institute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata, Japan.
ORCID-Profile: Shingo Kato, Kazufumi Honda
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Toyoda, T., Miura, N., Kato, S., Masuda, T., Ohashi, R., Matsushita, A., Matsuda, F., Ohtsuki, S., Katakura, A., & Honda, K. (2024). Identification of TPI1 As a potential therapeutic target in pancreatic cancer with dependency of TP53 mutation using multi‐omics analysis. Cancer Science. https://doi.org/10.1111/cas.16302
Vancouver
Toyoda T, Miura N, Kato S, Masuda T, Ohashi R, Matsushita A, et al. Identification of TPI1 As a potential therapeutic target in pancreatic cancer with dependency of TP53 mutation using multi‐omics analysis. Cancer Science. 2024. doi:10.1111/cas.16302
BibTeX
@article{Toyoda2024,
author = {Toyoda, Tomoaki and Miura, Nami and Kato, Shingo and Masuda, Takeshi and Ohashi, Ryuji and Matsushita, Akira and Matsuda, Fumio and Ohtsuki, Sumio and Katakura, Akira and Honda, Kazufumi},
title = {Identification of TPI1 As a potential therapeutic target in pancreatic cancer with dependency of TP53 mutation using multi‐omics analysis},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16302}
}
EUVIMED